Illumina Inc a decade of beads a handful

Illumina, Inc. . : : . a decade of beads. : : . a handful of lessons. : : . 6 October 2007 Illumina, Inc. - IGSP Talk Deirdre B. Parsons 1

Illumina, Inc. – The Big Picture • So where did the technology and the company come from? And why is it unique? – • What lessons can we as scientists learn from the Illumina story? – • Technology derived from an academic chemistry laboratory Development of Illumina’s technology teaches scientists commercialization lessons of their inventions What lessons can those in policy-making positions learn from this story? – Case study illustrates the intentions of the Bayh-Dole Act of 1980 6 October 2007 Illumina, Inc. - IGSP Talk Deirdre B. Parsons 2

What is Illumina today? 6 October 2007 Illumina, Inc. - IGSP Talk Deirdre B. Parsons 3

Technological Applications • SNP Genotyping • Gene Expression • Proteomics • Drug/pharmaceutical screening • Chemical/odor sensing 6 October 2007 Illumina, Inc. - IGSP Talk Deirdre B. Parsons 4

Illumina Partnerships • • • • • • Glaxo. Smith. Kline, PLC Chevron. Texaco Energy/Research Genome Quebec Innovation Centre The Wellcome Trust Sanger Institute National Center Biochip Technology Johns Hopkins University Whitehead Institute University of Tokyo Centre National de Genotypage University of Southern California University of California, Los Angeles Genomas, Inc. The Wellcome Trust Sanger Institute Galileo Genomics, Inc. / Genzion Biosciences, Inc. North American Rheumatoid Arthritis Consortium Invitrogen, Inc. National Cancer Institute Max-Planck Institute of Psychiatry PARC Team Pharmaco. Design Cancer Research UK: Edinburgh University Colon Cancer Genetics Group; Institute of Cancer Research; Cancer Research UK London Research Institute Aviagen, Inc. North Shore-Long Island Jewish Health System University of Pennsylvania, the Broad Institute, the CARe Consortium 6 October 2007 • • • • • • SAIC-Frederick, Inc. Center for Inherited Disease Research (CIDR) Shafallah Center de. CODE The Children's Hospital of Philadelphia Johnson & Johnson Pharmaceutical R&D, LLC Rea. Metrix Massachusetts General Hospital; Harvard Medical School The United States Department of Agriculture (USDA) Agricultural Research Service (ARS), the University of Missouri-Columbia (MU) and the University of Alberta (UA) Micro. Array Quality Control (MAQC) project: FDA, NIH, EPA and USDA Duke University Top 5 Pharmaceutical companies Amgen / Brigham & Women's Hospital Erasmus MC The Genome Institute of Singapore Children's Hospital of Eastern Ontario Mayo Clinic Asuragen de. CODE National Genome Research Network Golden Helix Integra. Gen National Institute of Genomic Medicine (INMEGEN) SNP Genetics Illumina, Inc. - IGSP Talk Deirdre B. Parsons 5

So where did it all begin? 6 October 2007 Illumina, Inc. - IGSP Talk Deirdre B. Parsons 6

David Walt, Ph. D. Department of Chemistry Tufts University 6 October 2007 Illumina, Inc. - IGSP Talk Deirdre B. Parsons 7

Technological Origins Sensor Target Covalent attachment Single optical fiber to camera for detection Major limitation: ONE sensor per fiber optic cable 6 October 2007 Illumina, Inc. - IGSP Talk Deirdre B. Parsons 8

Technological Development Single optical fiber 6 October 2007 Bundled optical fiber Illumina, Inc. - IGSP Talk Deirdre B. Parsons Pointed optical fiber 9

Optical fiber with wells… … and BEADS! Images courtesy of David R. Walt, Ph. D 6 October 2007 Illumina, Inc. - IGSP Talk Deirdre B. Parsons 10

Bead. Array Technology Pools of beads Binding changes dye color of bead Generation of random arrays Fluorescent light signals to detector 6 October 2007 Illumina, Inc. - IGSP Talk Deirdre B. Parsons 11

Business Finance Technology Chronology of Key Events Fast. Track Genotyping Beads in wells Pittsburgh Conference 1 M SNP Bead. Chip Hap. Map Project Series B financing IPO raises $103 Million Series A financing Series C financing Illumina founded Spyder acquired Solexa merger n. Genetics acquired 96 97 98 6 October 2007 99 00 01 Cy. Vera acquired 02 Illumina, Inc. - IGSP Talk Deirdre B. Parsons 03 04 05 06 07 12

Things to consider 1. This is a story about a company with unique technology 2. That technology was developed by a researcher • • 3. Hero story Balance of Open Science Norms and Commercialization Many factors impacted the success of the researcher, the technology and the company: • Knowledge of IP • • Timing Industrial partnerships Due diligence on many fronts Technology transfer 6 October 2007 Illumina, Inc. - IGSP Talk Deirdre B. Parsons 13

What does this mean for YOU? • Performing open academic science and commercializing your inventions is possible • Knowledge of intellectual property is the vehicle • Realistic expectations is a requirement 6 October 2007 Illumina, Inc. - IGSP Talk Deirdre B. Parsons 14

Acknowledgements Center for Genome Ethics, Law & Policy • Bob Cook-Deegan, MD • Subhashini Chandrasekharan, Ph. D Master’s Committee • Hunt Willard, Ph. D • Fred Dietrich, Ph. D Fuqua School of Business • Ronnie Chatterji, Ph. D Columbia University – School of Public Policy • Bhaven Sampat, Ph. D 6 October 2007 Tufts University • David Walt, Ph. D • Peggy Newell, Vice Provost • Martin Son, OTLIC • Nina Green, Director, OTLIC Illumina, Inc. • John Stuelpnagel, DVM • Todd Dickinson, Ph. D • Maurissa Bornstein Bio. Venture Investors • Marc Goldberg Illumina, Inc. - IGSP Talk Deirdre B. Parsons 15

C G A 6 October 2007 Illumina, Inc. - IGSP Talk Deirdre B. Parsons 16